Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Chimerix, Inc. CMRX
$1.09
-$0.06 (-5.60%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
102048307.00000000
-
week52high
4.32
-
week52low
1.09
-
Revenue
33824000
-
P/E TTM
1
-
Beta
1.15570900
-
EPS
1.86000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 22 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 22 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 07 июн 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 мая 2021 г. |
| Capital One | Overweight | 07 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jakeman David | D | 136752 | 3230 | 26 янв 2023 г. |
| Andriole Michael T. | A | 192825 | 192825 | 17 янв 2023 г. |
| Andriole Michael T. | A | 294899 | 32175 | 17 янв 2023 г. |
| Alrutz Michael Albert | A | 128550 | 128550 | 17 янв 2023 г. |
| Alrutz Michael Albert | A | 142015 | 21450 | 17 янв 2023 г. |
| Sherman Michael A. | A | 557050 | 557050 | 17 янв 2023 г. |
| Sherman Michael A. | A | 222995 | 92950 | 17 янв 2023 г. |
| Melemed Allen S. | A | 154260 | 154260 | 17 янв 2023 г. |
| Melemed Allen S. | A | 47887 | 25740 | 17 янв 2023 г. |
| Jakeman David | A | 24950 | 24950 | 17 янв 2023 г. |
Новостная лента
Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 17:41
Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Allen Melemed - Chief Medical Officer Mike Andriole - Chief Financial and Business Officer Josh Allen - Chief Technology Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Securities Ed White - H.C. Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2023 Earnings Conference Call.
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
GlobeNewsWire
27 апр 2023 г. в 07:00
DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview.
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
InvestorPlace
05 апр 2023 г. в 13:40
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.
The Top 7 Growth Stocks in Biotech
InvestorPlace
03 мар 2023 г. в 18:57
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript
Seeking Alpha
02 мар 2023 г. в 10:36
Chimerix, Inc. (NASDAQ:CMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Josh Allen - Chief Technology Officer of Imipridones Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Joseph Thome - TD Cowen Naureen Quibria - Capital One Securities Soumit Roy - Jones Research Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2022 Earnings Conference Call. I would now like to introduce your host for today's call Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix.